Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Shares Outstanding (Weighted Average) (2016 - 2025)

Mimedx (MDXG) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $147.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 0.55% to $147.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $147.8 million through Dec 2025, up 0.55% year-over-year, with the annual reading at $147.8 million for FY2025, 0.55% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $147.8 million in Q4 2025 for Mimedx, roughly flat from $147.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $147.8 million in Q4 2025 to a low of $109.4 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $126.6 million across 5 years, with a median of $115.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 27.98% in 2024 and later rose 0.3% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $110.4 million in 2021, then rose by 2.32% to $112.9 million in 2022, then increased by 3.18% to $116.5 million in 2023, then rose by 26.17% to $147.0 million in 2024, then rose by 0.55% to $147.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MDXG at $147.8 million in Q4 2025, $147.7 million in Q3 2025, and $147.8 million in Q2 2025.